MX2017011434A - Compuestos heterociclicos triciclicos sustituidos. - Google Patents

Compuestos heterociclicos triciclicos sustituidos.

Info

Publication number
MX2017011434A
MX2017011434A MX2017011434A MX2017011434A MX2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A MX 2017011434 A MX2017011434 A MX 2017011434A
Authority
MX
Mexico
Prior art keywords
heterocyclic compounds
compounds
tricyclic heterocyclic
substituted tricyclic
cr3r3
Prior art date
Application number
MX2017011434A
Other languages
English (en)
Spanish (es)
Inventor
G Murali Dhar T
Xiao Hai-Yun
Jiang Bin
Duan Jingwu
J Tebben Andrew
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2017011434A publication Critical patent/MX2017011434A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
MX2017011434A 2015-03-18 2016-03-17 Compuestos heterociclicos triciclicos sustituidos. MX2017011434A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134769P 2015-03-18 2015-03-18
PCT/US2016/022737 WO2016149436A1 (en) 2015-03-18 2016-03-17 Substituted tricyclic heterocyclic compounds

Publications (1)

Publication Number Publication Date
MX2017011434A true MX2017011434A (es) 2018-01-25

Family

ID=55640932

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011434A MX2017011434A (es) 2015-03-18 2016-03-17 Compuestos heterociclicos triciclicos sustituidos.

Country Status (14)

Country Link
US (1) US10189840B2 (enExample)
EP (1) EP3271360B1 (enExample)
JP (1) JP6793657B2 (enExample)
KR (1) KR102654709B1 (enExample)
CN (1) CN107635993B (enExample)
AU (1) AU2016233288A1 (enExample)
BR (1) BR112017019773A2 (enExample)
CA (1) CA2980159A1 (enExample)
EA (1) EA032315B1 (enExample)
ES (1) ES2797805T3 (enExample)
IL (1) IL254424A0 (enExample)
MX (1) MX2017011434A (enExample)
SG (1) SG11201707469WA (enExample)
WO (1) WO2016149436A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017019731A2 (pt) 2015-03-18 2018-05-22 Bristol-Myers Squibb Company compostos heterocíclicos tricíclicos úteis como inibidores de tnf
ES2803650T3 (es) 2015-03-18 2021-01-28 Bristol Myers Squibb Co Compuestos heterocíclicos útiles como inhibidores de TNF
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
EP3331889B1 (en) 2015-08-03 2020-09-23 Bristol-Myers Squibb Company Cyclic compounds useful as modulators of tnf alpha
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3596078B1 (en) * 2017-03-15 2023-04-12 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of tnf activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038397B2 (ja) * 1980-03-06 1985-08-31 エスエス製薬株式会社 チアジノイミダゾ−ル誘導体及びその製造法
ATE238998T1 (de) 1997-02-25 2003-05-15 Us Gov Health & Human Serv Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
AU7922900A (en) * 1999-10-27 2001-05-08 Novartis Ag Thiazole and imidazo (4,5-b) pyridine compounds and their pharmaceutical use
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
EP1479681A4 (en) 2002-01-31 2006-05-10 Daiichi Seiyaku Co IMIDAZO (1,2-a) pyridine
WO2004050035A2 (en) 2002-12-03 2004-06-17 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
AU2008267443A1 (en) * 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
WO2009045174A1 (en) 2007-10-05 2009-04-09 S*Bio Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
EP2411057B1 (en) 2009-03-23 2020-05-06 Eli Lilly and Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
CA2874303C (en) 2012-06-11 2020-10-13 Ucb Biopharma Sprl Tnf -alpha modulating benz imidazoles
US9309243B2 (en) 2012-07-13 2016-04-12 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015086519A1 (en) 2013-12-09 2015-06-18 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3080085B1 (en) 2013-12-09 2019-08-14 UCB Biopharma SPRL Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
KR20230035424A (ko) 2014-10-06 2023-03-13 시그날 파마소티칼 엘엘씨 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법
BR112017019731A2 (pt) 2015-03-18 2018-05-22 Bristol-Myers Squibb Company compostos heterocíclicos tricíclicos úteis como inibidores de tnf
ES2803650T3 (es) 2015-03-18 2021-01-28 Bristol Myers Squibb Co Compuestos heterocíclicos útiles como inhibidores de TNF

Also Published As

Publication number Publication date
EP3271360A1 (en) 2018-01-24
KR20170129810A (ko) 2017-11-27
EA201792034A1 (ru) 2018-03-30
US10189840B2 (en) 2019-01-29
SG11201707469WA (en) 2017-10-30
BR112017019773A2 (pt) 2018-05-15
IL254424A0 (en) 2017-11-30
JP2018508553A (ja) 2018-03-29
WO2016149436A1 (en) 2016-09-22
CN107635993A (zh) 2018-01-26
AU2016233288A1 (en) 2017-11-09
EA032315B1 (ru) 2019-05-31
EP3271360B1 (en) 2020-04-22
ES2797805T3 (es) 2020-12-03
KR102654709B1 (ko) 2024-04-03
US20180111936A1 (en) 2018-04-26
CA2980159A1 (en) 2016-09-22
JP6793657B2 (ja) 2020-12-02
CN107635993B (zh) 2020-05-22

Similar Documents

Publication Publication Date Title
HK1252623A1 (zh) 可用作TNFα调节剂的杂环化合物
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA202091483A1 (ru) Амидзамещенные индольные соединения, пригодные в качестве ингибиторов tlr
MX2017011433A (es) Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
EA202091484A1 (ru) 4-азаиндольные соединения
WO2019126253A8 (en) Aryl and heteroaryl substituted indole compounds
EA201992674A1 (ru) Тиенопиридины и бензотиофены в качестве ингибиторов irak4
MX2020005873A (es) Compuestos de 6-azaindol.
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
MX2017011577A (es) Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).
MY196474A (en) [1,2,4]Triazolo[1,5-A]Pyridinyl Substituted Indole Compounds
MY191796A (en) Heterocyclic compounds as lsd1 inhibitors
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
EA201791293A1 (ru) Сайт-специфическое дозирование ингибитора btk
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201991029A1 (ru) Ингибиторы magl
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
MX383074B (es) Compuestos de naftiridina como inhibidores de quinasa jak
EA201790766A1 (ru) Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
MX2018001173A (es) Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa.